Lv51
910 积分 2021-12-16 加入
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
10小时前
已完结
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
3天前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
8天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
15天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Making Progress Along the Challenging Road of Drug Development for Patients With EGFR Exon 20 Insertion–Positive Non–Small Cell Lung Cancer
2个月前
已完结
Lung cancer screening in people who have never smoked: lessons from East Asia
2个月前
已关闭
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
2个月前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
2个月前
已完结
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
3个月前
已完结
皖公网安备34019202002308
